Papillomaviruses

Principles and Practice of Clinical Virology: Sixth Edition

Volumn , Issue , 2009, Pages 807-822

  McCance, Dennis ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

HPV infection and abnormal cervix; Hybrid capture method; Loop Electrosurgical Excision Procedure (LEEP); Membrane associated guanylate kinase (MAGUK); Oncogenic potential of papillomaviruses; Papillomavirus; Physical and chemical properties; Viral replication

Indexed keywords

EID: 84890253589     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470741405.ch33     Document Type: Chapter

References (41)

1. Antinore, M.J., Birrer, M.J., Patel, D. et al. (1996) The human papillomavirus type 16 E7 gene product interacts with and trans-activates the AP1 family of transcription factors. EMBO Journal, 15, 1950-60.
2. Bauer, H.M., Ting, Y., Greer, C.E. et al. (1991) Genital human papillomavirus infection in female university students as determined by a PCR-based method. Journal of the American Medical Association, 265, 472-77.
3. Bonnez, W., Darin, C., Borkhuis, C. et al. (1998) Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse. Journal of Virology, 72, 5256-61.
4. Brehm, A., Miskka, E.A., McCance, D.J. et al. (1998) Retinoblastome protein recruits histone deacetylase to repress transcription. Nature, 391, 597-601.
5. Bunney, M. (1982) Viral Warts: Their Biology and Treatment, Oxford University Press, Oxford.
6. Chen, J.J., Reid, C.E., Band, V. and Androphy, E.J. (1995) Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science, 269, 529-31.
7. Conrad, M., Bubb, V.J. and Schlegel, R. (1993) The human papillomavirus type 6 and 16 E5 proteins are membrane-associated proteins which associate with the 16-kilodalton pore-forming protein. Journal of Virology, 67, 6170-78.
8. Davy, C.E., Jackson, D.J., Raj, K. et al. (2005) Human papillomavirus type 16 E1 E4-induced G2 arrest is associated with cytoplasmic retention of active Cdk1/cyclin B1 complexes. Journal of Virology, 79, 3998-4011.
9. De Roda Husman, A.M., Walboomers, J.M., Van Den Brule, A.J. et al. (1995) The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. Journal of General Virology, 76, 1057-62.
10. Doorbar, J., Ely, S., Sterling, J. et al. (1991) Specific interaction between HPV-16 E1-E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network. Nature, 352, 824-27.
11. van Doorn, L.-J., Quint, W., Kleter, B. et al. (2002) Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF10 line probe assay. Journal of Clinical Microbiology, 40, 979-83.
12. Durst, M., Gissmann, L., Ikenberg, H. and Zur Hausen, H. (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proceedings of the National Academy of Sciences of the United States of America, 80, 3812-15.
13. Dyson, N., Howley, P.M., Munger, K. and Harlow, E. (1989) The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 243, 934-37.
14. Frattini, M.G. and Laimins, L.A. (1994) Binding of the human papillomavirus E1 origin-recognition protein is regulated through complex formation with the E2 enhancer-binding protein. Proceedings of the National Academy of Sciences of the United States of America, 91, 12398-402.
15. Frattini, M., Lim, H. and Laimins, L.A. (1996) In vitro synthesis of oncogenic human papillomaviruses requires episomal templates for differentiation-dependent late expression. Proceedings of the National Academy of Sciences of the United States America, 91, 3062-67.
16. Gravitt, P.E., Peyton, C.L., Apple, R.J. and Wheeler, C.M. (1998) Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. Journal of Clinical Microbiology, 36, 3020-27.
17. Harper, D.M., Franco, E.L., Wheeler, C.M. et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet, 367, 1247-55.
18. Kirnbauer, R., Booy, F., Cheng, N. et al. (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proceedings of the National Academy of Sciences of the United States of America, 89, 12180-84.
19. Kleter, B., van Doorn, L.J., ter Schegget, J. et al. (1998) Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. American Journal of Pathology, 153, 1731-39.
20. Knight, G.L., Turnell, A.S. and Roberts, S. (2006) Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins. Journal of Virology, 80, 7416-26.
21. Kreider, J.W., Howett, M.K., Wolfe, S.A. et al. (1985) Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. Nature, 317, 639-41.
22. Kurman, R.J., Henson, D.E., Herbst, A.L. et al. (1994) Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. Journal of the American Medical Association, 271, 1866-69.
23. Lee, C. and Laimins, L.A. (2004) Role of the PDZ domain-binding motif of the oncoprotein E6 in the pathogenesis of human papillomavirus type 31. Journal of Virology, 78, 12366-77.
24. Leechanachai, P., Banks, L., Moreau, F. and Matlashewski, G. (1992) The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene, 7, 19-25.
25. Lu, J.Z., Sun, Y.N., Rose, R.C. et al. (1993) Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin. Journal of Virology, 67, 7131-39.
26. McCance, D.J. (1998) Human papillomaviruses and cervical cancer [editorial]. Journal of Medical Microbiology, 47, 371-73.
27. McCance, D.J., Kalache, A., Ashdown, K. et al. (1986) Human papillomavirus types 16 and 18 in carcinomas of the penis from Brazil. International Journal of Cancer, 37, 55-59.
28. McCance, D.J., Kopan, R., Fuchs, E. and Laimins, L.A. (1988) Human papillomavirus type 16 alters human epithelial cell differentiation in vitro. Proceedings of the National Academy of Sciences of the United States of America, 85, 7169-73.
29. McMurray, H.R. and McCance, D.J. (2004) Degradation of p53, not telomerase activation, by E6 is required for bypass of crisis and immortalization by human papillomavirus type 16 E6/E7. Journal of Virology, 78, 5698-706.
30. McMurray, H.R., Nguyen, D., Westbrook, T.F. and Mccance, D.J. (2001) Biology of human papillomaviruses. International Journal of Experimental Pathology, 82, 15-33.
31. Oriel, J.D. (1971) Natural history of genital warts. British Journal of Venereal Diseases, 47, 1-13.
32. Phillips, A.C. and Vousden, K.H. (1997) Analysis of the interaction between human papillomavirus type 16 E7 and the TATA-binding protein, TBP. Journal of General Virology, 78, 905-909.
33. Rose, R.C., Bonnez, W., Da Rin, C. et al. (1994) Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. Journal of General Virology, 75, 2445-49.
34. Scheffner, M., Werness, B.A., Huibregtse, J.M. et al. (1990) The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell, 63, 1129-36.
35. Shai, A., Brake, T., Somoza, C. and Lambert, P.F. (2007) The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Research, 67, 1626-35.
36. Singer, A. and Walker, P. (1985) The treatment of CIN: conservative methods. Clinics in Obstetrics and Gynaecology, 12, 121-32.
37. Straight, S.W., Herman, B. and McCance, D.J. (1995) The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes. Journal of Virology, 69, 3185-92.
38. Thomas, M., Glaunsinger, B., Pim, D. et al. (2001) HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene, 20, 5431-39.
39. Villa, L.L., Costa, R.L., Petta, C.A. et al. (2005) Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The Lancet Oncology, 6, 271-78.
40. Walker, P.G., Singer, A., Dyson, J.L. et al. (1983) Colposcopy in the diagnosis of papillomavirus infection of the uterine cervix. British Journal of Obstetrics and Gynaecology, 90, 1082-86.
41. Wheeler, C.M. (2007) Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nature Clinical Practice Oncology, 4, 224-35.